JAMA子刊:机械取栓对ASPECTS评分低分的卒中患者的结果

2022-02-20 MedSci原创 MedSci原创

超过五分之一的ASPECTS为2-5的患者在MT后实现了90天功能独立。

关于机械血栓切除术(MT)对现实世界中出现大面积核心梗死的中风患者的治疗效果,目前数据有限。为了研究大血管闭塞且ASPECTS评分为2-5分的患者进行机械血栓切除术的安全性和有效性。来自南卡罗来纳医科大学神经外科的专家开展了一项研究,结果发表在JAMA Network Open杂志上。

这项回顾性队列研究使用了来自中风血栓切除术和动脉瘤登记处(STAR)的数据,该登记处结合了美国、欧洲和亚洲的28个具有血栓切除能力的中风中心的前瞻性数据库。该研究包括颈内动脉或大脑中动脉M1段闭塞的2345名患者。患者在干预后被随访了90天。

ASPECTS是一个10分制的评分系统,基于基线无对比计算机断层扫描的早期缺血变化程度,10分表示正常。所有的患者都接受了MT。主要结果和措施是90天的良好结果(mRS评分为0-2)相关的因素,包括ASPECTS为2-5和在延长的窗口期(从症状出现的6-24小时)接受MT的交互项。

共纳入2345名接受MT治疗的患者(1175名女性[50.1%];中位年龄,72岁[IQR,60-80岁];2132名患者[90.9%]的ASPECTS≥6,213名患者[9.1%]的ASPECTS为2-5)。在90天时,213名ASPECTS为2至5的患者中,有47名(22.1%)mRS评分为0至2(25.6%[176名中的45名]的患者接受了成功的再通疗法[改良脑缺血溶栓评分≥2B],与5.4%[37名中的2名]的患者接受了不成功的再通疗法;P = 0.007)。

在控制了潜在的混杂因素后,低ASPECTS(OR=0.60;95%CI,0.38-0.85;P = .002)和在扩展窗口出现(OR=0.69;95%CI,0.55-0.88;P = .001)与较差的90天结果有关,这两个因素之间没有明显的交互作用(P = .64)。

在这项队列研究中,超过五分之一的ASPECTS为2-5的患者在MT后实现了90天功能独立。低ASPECTS的患者成功再通的可能性几乎是5倍。低ASPECTS与90天结果的关系,在早期与延长的MT窗口期的病人中并无不同。

 

参考文献:

Outcomes of Mechanical Thrombectomy for Patients With Stroke Presenting With Low Alberta Stroke Program Early Computed Tomography Score in the Early and Extended Window. JAMA Netw Open. 2021;4(12):e2137708. doi:10.1001/jamanetworkopen.2021.37708

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1647749, encodeId=534e164e74989, content=<a href='/topic/show?id=883828e714' target=_blank style='color:#2F92EE;'>#ASPECTS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2877, encryptionId=883828e714, topicName=ASPECTS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37d23475396, createdName=liye789132259, createdTime=Sun Jul 03 14:22:15 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720447, encodeId=c2861e2044717, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Nov 16 14:22:15 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729374, encodeId=0a651e293740e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 12 07:22:15 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461977, encodeId=7dc514619e774, content=<a href='/topic/show?id=10bf5438bc' target=_blank style='color:#2F92EE;'>#CTS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5438, encryptionId=10bf5438bc, topicName=CTS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479116, encodeId=fb2314e911637, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578915, encodeId=c61415e8915de, content=<a href='/topic/show?id=80286123908' target=_blank style='color:#2F92EE;'>#机械取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61239, encryptionId=80286123908, topicName=机械取栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0216462203, createdName=ms2186806800017884, createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1647749, encodeId=534e164e74989, content=<a href='/topic/show?id=883828e714' target=_blank style='color:#2F92EE;'>#ASPECTS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2877, encryptionId=883828e714, topicName=ASPECTS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37d23475396, createdName=liye789132259, createdTime=Sun Jul 03 14:22:15 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720447, encodeId=c2861e2044717, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Nov 16 14:22:15 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729374, encodeId=0a651e293740e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 12 07:22:15 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461977, encodeId=7dc514619e774, content=<a href='/topic/show?id=10bf5438bc' target=_blank style='color:#2F92EE;'>#CTS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5438, encryptionId=10bf5438bc, topicName=CTS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479116, encodeId=fb2314e911637, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578915, encodeId=c61415e8915de, content=<a href='/topic/show?id=80286123908' target=_blank style='color:#2F92EE;'>#机械取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61239, encryptionId=80286123908, topicName=机械取栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0216462203, createdName=ms2186806800017884, createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1647749, encodeId=534e164e74989, content=<a href='/topic/show?id=883828e714' target=_blank style='color:#2F92EE;'>#ASPECTS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2877, encryptionId=883828e714, topicName=ASPECTS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37d23475396, createdName=liye789132259, createdTime=Sun Jul 03 14:22:15 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720447, encodeId=c2861e2044717, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Nov 16 14:22:15 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729374, encodeId=0a651e293740e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 12 07:22:15 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461977, encodeId=7dc514619e774, content=<a href='/topic/show?id=10bf5438bc' target=_blank style='color:#2F92EE;'>#CTS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5438, encryptionId=10bf5438bc, topicName=CTS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479116, encodeId=fb2314e911637, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578915, encodeId=c61415e8915de, content=<a href='/topic/show?id=80286123908' target=_blank style='color:#2F92EE;'>#机械取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61239, encryptionId=80286123908, topicName=机械取栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0216462203, createdName=ms2186806800017884, createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=)]
    2022-12-12 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1647749, encodeId=534e164e74989, content=<a href='/topic/show?id=883828e714' target=_blank style='color:#2F92EE;'>#ASPECTS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2877, encryptionId=883828e714, topicName=ASPECTS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37d23475396, createdName=liye789132259, createdTime=Sun Jul 03 14:22:15 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720447, encodeId=c2861e2044717, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Nov 16 14:22:15 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729374, encodeId=0a651e293740e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 12 07:22:15 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461977, encodeId=7dc514619e774, content=<a href='/topic/show?id=10bf5438bc' target=_blank style='color:#2F92EE;'>#CTS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5438, encryptionId=10bf5438bc, topicName=CTS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479116, encodeId=fb2314e911637, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578915, encodeId=c61415e8915de, content=<a href='/topic/show?id=80286123908' target=_blank style='color:#2F92EE;'>#机械取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61239, encryptionId=80286123908, topicName=机械取栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0216462203, createdName=ms2186806800017884, createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=)]
    2022-02-19 docwu2019
  5. [GetPortalCommentsPageByObjectIdResponse(id=1647749, encodeId=534e164e74989, content=<a href='/topic/show?id=883828e714' target=_blank style='color:#2F92EE;'>#ASPECTS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2877, encryptionId=883828e714, topicName=ASPECTS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37d23475396, createdName=liye789132259, createdTime=Sun Jul 03 14:22:15 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720447, encodeId=c2861e2044717, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Nov 16 14:22:15 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729374, encodeId=0a651e293740e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 12 07:22:15 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461977, encodeId=7dc514619e774, content=<a href='/topic/show?id=10bf5438bc' target=_blank style='color:#2F92EE;'>#CTS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5438, encryptionId=10bf5438bc, topicName=CTS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479116, encodeId=fb2314e911637, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578915, encodeId=c61415e8915de, content=<a href='/topic/show?id=80286123908' target=_blank style='color:#2F92EE;'>#机械取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61239, encryptionId=80286123908, topicName=机械取栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0216462203, createdName=ms2186806800017884, createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1647749, encodeId=534e164e74989, content=<a href='/topic/show?id=883828e714' target=_blank style='color:#2F92EE;'>#ASPECTS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2877, encryptionId=883828e714, topicName=ASPECTS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a37d23475396, createdName=liye789132259, createdTime=Sun Jul 03 14:22:15 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720447, encodeId=c2861e2044717, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed Nov 16 14:22:15 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729374, encodeId=0a651e293740e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 12 07:22:15 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461977, encodeId=7dc514619e774, content=<a href='/topic/show?id=10bf5438bc' target=_blank style='color:#2F92EE;'>#CTS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5438, encryptionId=10bf5438bc, topicName=CTS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479116, encodeId=fb2314e911637, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578915, encodeId=c61415e8915de, content=<a href='/topic/show?id=80286123908' target=_blank style='color:#2F92EE;'>#机械取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61239, encryptionId=80286123908, topicName=机械取栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de0216462203, createdName=ms2186806800017884, createdTime=Sat Feb 19 00:22:15 CST 2022, time=2022-02-19, status=1, ipAttribution=)]

相关资讯

2012国际卒中大会:卒中血管内治疗转归与ASPECTS相关

 2012国际卒中大会公布的START研究初步结果显示,CTA原始图像所示的治疗前艾伯塔卒中方案早期CT评分(ASPECTS)较高与血管内治疗后转归较好相关。NCCT与ASPECTS对比研究为确定其转归预测相对准确性所必需。   目前尚无用于选择患者行血管内卒中治疗(EVT)的标准成像方法。CT依然是应用最为广泛的卒中评价方法,并且ASPECTS定量的非强化CT缺血改变(NCCT

Neurology: ASPECTS与CT灌对急性前循环卒中梗死灶检测准确性比较

CT灌注与ASPECTS对急性前循环卒中梗死灶检测准确性无显著差异

Radiology:ASPECTS区域X线密度改变与急性缺血性脑卒中动脉取栓时间窗

背景:近期研究表明经高级CT或MRI技术评价后,急性脑卒中患者发病24小时行取栓术的价值。超时间窗的治疗在临床应用中仍然是一个挑战,并且许多脑卒中中心常规并不进行高级影像学检查。本研究旨在评价是否能够通过CT平扫自动脑实质密度测量来获取CT灌注定义的缺血性核心的信息,并作为取栓术的最晚时间窗。

拓展阅读

JNNP:较大核心缺血性脑卒中的血管内治疗——随机对照临床试验及荟萃分析

对于较大核心 AIS(由 ASPECTS 2-5 或容积法评估)患者,EVT 似乎有效且安全。

RESCUE研究:ASPECT评分与大血管闭塞导致的卒中患者的血管内治疗的有效性和安全性之间的关系

EVT与急性大血管闭塞性卒中患者且ASPECTS为4-5患者的90天功能改善有关。

Radiology:ASPECTS区域X线密度改变与急性缺血性脑卒中动脉取栓时间窗

背景:近期研究表明经高级CT或MRI技术评价后,急性脑卒中患者发病24小时行取栓术的价值。超时间窗的治疗在临床应用中仍然是一个挑战,并且许多脑卒中中心常规并不进行高级影像学检查。本研究旨在评价是否能够通过CT平扫自动脑实质密度测量来获取CT灌注定义的缺血性核心的信息,并作为取栓术的最晚时间窗。

Neurology: ASPECTS与CT灌对急性前循环卒中梗死灶检测准确性比较

CT灌注与ASPECTS对急性前循环卒中梗死灶检测准确性无显著差异

2012国际卒中大会:卒中血管内治疗转归与ASPECTS相关

 2012国际卒中大会公布的START研究初步结果显示,CTA原始图像所示的治疗前艾伯塔卒中方案早期CT评分(ASPECTS)较高与血管内治疗后转归较好相关。NCCT与ASPECTS对比研究为确定其转归预测相对准确性所必需。   目前尚无用于选择患者行血管内卒中治疗(EVT)的标准成像方法。CT依然是应用最为广泛的卒中评价方法,并且ASPECTS定量的非强化CT缺血改变(NCCT